True to the vision of the company, which states “To be globally recognized as a science based integrated drug product development service provider to the health care industry”, RA Chem Pharma Ltd views Research and Development as a vital component of business strategy that will provide a long-term competitive advantage.
Our R&D facility is housed in 106250 sft along with in-house Analytical Laboratory in 2300 sft, located in CDC Towers, Nacharam, Hyderabad. It has more than 50 diligent and committed scientists, working on different types of solid dosage forms, ranging from immediate release to modified release to multi-layered dosage forms, encompassing a wide range of compounds and houses a range of state of the art equipment for both formulation and analytical development. Our core specialty lies in modified release multi-particulate drug delivery systems.
RA Chem Pharma also has an equally well equipped API lab to synthesize high value niche API.
The formulation R&D division successfully developed generic versions of Methocarbamol tablets, which turned out be the first ANDA submission for the company. In addition to this key products like Itraconazole, Duloxetine and MebeverineHCl were developed. Itraconazole and Duloxetine capsules would eventually be the products that would be filed in USA. Duloxetine and Mebeverine capsules would eventually be the products that would give the company its European filings.
Going forward the R&D divisions would be oriented with a global vision to realize strategic objectives and to surpass the world level in this dominant field through independent research.
Formulation (Major Equipment)
Analytical (Major Equipment)